8-methyl-8-azabicyclo[3.2.1]oct-3-yl 1H-indole-3-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 8-methyl-8-azabicyclo[3.2.1]oct-3-yl 1H-indole-3-carboxylate
• 英文别名: (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 1H-indole-3-carboxylate
• 化学式: C₁₇H₂₀N₂O₂
• 分子量: 284.35
• InChiKey: ZNRGQMMCGHDTEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  45.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  8-methyl-8-azabicyclo[3.2.1]oct-3-yl 1H-indole-3-carboxylate 生成 (8-methyl-8-oxido-8-azoniabicyclo[3.2.1]octan-3-yl) 1H-indole-3-carboxylate
  参考文献：
  名称：

  GIGER, RUDOLF K. A.;ENGEL, GUNTER;BUCHHEIT, KARL-HEINZ

  摘要：

  DOI：

文献信息

• Formulations of adenosine a1 agonists
  申请人：——

  公开号：US20030018008A1

  公开（公告）日：2003-01-23

  The present invention provides a method of treating conditions associated with pain and alleviating the symptoms associated therewith which comprises administering to a mammal, including man, an adenosine A1 agonist or a physiologically acceptable salt or solvate thereof and a 5HT 3 antagonist or a physiologically acceptable salt or solvate thereof. The present invention also provides pharmaceutical formulations and patient packs comprising said combinations.

  本发明提供了一种治疗与疼痛相关的症状并缓解相关症状的方法，包括向哺乳动物，包括人类，施用腺苷A1受体激动剂或其生理上可接受的盐或溶剂以及5HT3拮抗剂或其生理上可接受的盐或溶剂。本发明还提供了包含这些组合物的药物配方和患者包。
• Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders
  申请人：Fraser Oliver Matthew

  公开号：US20050113421A1

  公开（公告）日：2005-05-26

  A method is provided for using Cav2.2 subunit calcium channel modulators, particularly thiazolidinone, oxazolidinone, and imidazolone derivatives, to treat non-inflammatory gastrointestinal tract disorders.

  提供了一种方法，用于使用Cav2.2亚单位钙通道调节剂，特别是噻唑啉酮、噁唑啉酮和咪唑啉酮衍生物，来治疗非炎症性胃肠道疾病。
• Tropinol esters and related compounds to promote normal processing of APP
  申请人：John Varghese

  公开号：US11325904B2

  公开（公告）日：2022-05-10

  In various embodiments, compositions and methods are provided for treatment and/or prevention of amyloidogenic diseases. In certain embodiments, the methods entail administering an effective amount of a tropinol ester to a subject in need thereof for prophylactic or therapeutic effect. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In certain embodiments, methods of reducing the risk, lessening the severity, or delaying the progression or onset of a disease characterized by beta-amyloid deposits in the brain of a mammal are also provided. In certain embodiments, methods of directly or indirectly inhibiting the C-terminal cleavage of APP resulting in the formation of APP-C31 peptide and APPneo (AP-P664) in a mammal are provided.

  在各种实施方式中，提供了用于治疗和/或预防淀粉样病变疾病的组合物和方法。在某些实施方式中，该方法包括向需要预防或治疗作用的受试者施用有效量的tropinol酯，以达到预防或治疗效果。该方法特别适用于预防和治疗阿尔茨海默病。在某些实施方式中，还提供了减少哺乳动物大脑中β-淀粉样沉积所致疾病的风险、减轻其严重程度或延缓其进展或发作的方法。在某些实施方式中，还提供了直接或间接抑制APP的C-末端裂解，从而形成APP-C31肽和APPneo（AP-P664）的方法。
• 5HT-3 antagonists for prevention of dependence
  申请人：SANDOZ AG

  公开号：EP0302008A2

  公开（公告）日：1989-02-01

  The invention provides use of a 5HT-3 antagonist in the manufacture of a medicament suitable for the prevention or reduction of dependence on a dependence-inducing agent.

  本发明提供了 5HT-3 拮抗剂在制造适用于预防或减少对依赖性诱导剂依赖的药物中的用途。
• Use of 5-hydroxytryptamine-antagonists in the treatment of mental disorders originating in childhood
  申请人：GLAXO GROUP LIMITED

  公开号：EP0450757A2

  公开（公告）日：1991-10-09

  The invention relates to the use of a compound which acts as an antagonist of 5-HT at 5-HT₃ receptors in the treatment of autism or another disorder originating in childhood in which there is mental retardation.

  本发明涉及一种在 5-HT₃ 受体上作为 5-HT 拮抗剂的化合物在治疗自闭症或另一种源于儿童期的精神发育迟滞疾病中的应用。